Allan H. Friedman

Neurosurgeon-in-Chief Division of Neurosurgery/Department of Surgery
Duke University Medical Center

Disclosure: NO DISCLOSURE DATA

Presentation(s):

• ATIM-24 - Dose finding and dose expansion trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG)

  Friday, November 22
  7:30 PM – 9:30 PM

• ATIM-27 - Tumor mutational burden predicts response to Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in malignant glioma patients: Assessment of transcriptional and immunological correlates.

  Saturday, November 23
  5:00 PM – 7:00 PM

• ATIM-31 - Safety of Tumor-Specific Peptide Vaccine Targeting Isocitrate Dehydrogenase 1 Mutation in Recurrent Resectable Low Grade Glioma Patients

  Sunday, November 24
  9:50 AM – 9:55 AM